We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

CETA and Canadian IP law: Possible changes ahead?
  • Gowling WLG
  • Canada, European Union
  • March 3 2016

In 2013, an agreement in principle was reached between Canada and the European Union - theCanada-European Union Comprehensive Economic and Trade


Methods of medical treatment claims issues in Canada, US and Europe
  • Gowling WLG
  • Canada, European Union, USA
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe


Eli Lilly Canada Inc. v. Apotex Inc (2010 FCA 240)
  • Gowling WLG
  • Canada
  • October 27 2010

This was an appeal of the decision of Madame Justice Gauthier (in the Federal Court) who had found that although Lilly met its burden to prove that Apotex infringed eight Lilly process patents related to the manufacture of the antibiotic cefaclor for material imported before June 3, 1998, Lilly failed to do so for the cefaclor imported into Canada after June 3, 1998


Time for change? Potential impact of Canada’s trade negotiations on pharma patents
  • Gowling WLG
  • Canada
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this


Impacts of the Amazon.com decisions on medical use claims in Canada
  • Gowling WLG
  • Canada
  • July 13 2012

Methods of medical treatment and surgery are not statutory subject matter in Canada


AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case
  • Gowling WLG
  • Canada
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing


Novopharm v. Eli Lilly, appeals of decisions of the Case Management Prothonotary
  • Gowling WLG
  • Canada
  • May 21 2010

Eli Lilly appealed two interlocutory decisions made by the Case Management Prothonotary


Merck v. Pharmascience, PMNOC Regulations decision
  • Gowling WLG
  • Canada
  • May 21 2010

The Court, in a lengthy decision, dismissed an application for prohibition in respect of the drug finasteride, wherein allegations of invalidity had been raised, including grounds of double-patenting, novelty and obviousness


Novopharm Limited v. Pfizer Canada inc. (2010 FCA 242)
  • Gowling WLG
  • Canada
  • October 27 2010

Novopharm appealed the decision of the Federal Court to grant an order of prohibition to Pfizer in respect of Novopharm’s generic version of VIAGRA


Eli Lilly Canada inc. v. Apotex Inc. (2010 FC 952)
  • Gowling WLG
  • Canada
  • October 27 2010

Apotex brought a motion to set aside an Order from 2007 granting Eli Lilly’s applications for a prohibition Order in PMNOC proceedings